Figures computed from official regulatory filings — .
Analysttarget 80.43 USD (+214%) · consensus 5/5 · 9 buy · 0 hold · 0 sell
Ownershipinsiders 6.98% · institutions 88.97% · short 19.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Neurogene Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
101 buys61 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| McMinn Rachel | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| McMinn Rachel | Exercise | $19.1K | SEC |
| Cvijic Christine Mikail | Sell | $21.6K | SEC |
| Cvijic Christine Mikail | Sell | $151.8K | SEC |
| Cvijic Christine Mikail | Sell | $53.9K | SEC |
| Cvijic Christine Mikail | Sell | $87.5K | SEC |
| Cvijic Christine Mikail | Sell | $25.2K | SEC |
| Woods Keith | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Woods Keith | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Woods Keith | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cvijic Christine Mikail | Sell | $144.4K | Unusual size | SEC |
| Cvijic Christine Mikail | Sell | $155.7K | Unusual size | SEC |
| Shafer Christina | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| McMinn Rachel | Sell | $74K | SEC |
| Cvijic Christine Mikail | Sell | $55.3K | SEC |
| Jordan Julie | Sell | $18.1K | Unusual size | SEC |
| Cobb Stuart | Sell | $56.7K | SEC |
| Cvijic Christine Mikail | Sell | $5.8K | SEC |
| Cvijic Christine Mikail | Sell | $48.7K | SEC |
| Cobb Stuart | Sell | $81.5K | SEC |
| Cvijic Christine Mikail | Sell | $29.6K | SEC |
| Cobb Stuart | Sell | $3.3K | SEC |
| Cvijic Christine Mikail | Sell | $120.5K | SEC |
| Freedland Cory S. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cobb Stuart | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |